Article
Biochemistry & Molecular Biology
Nerea Ugartondo, Nuria Martinez-Gil, Monica Esteve, Natalia Garcia-Giralt, Neus Roca-Ayats, Diana Ovejero, Xavier Nogues, Adolfo Diez-Perez, Raquel Rabionet, Daniel Grinberg, Susanna Balcells
Summary: Osteoporosis, a common metabolic bone disorder, is often treated with nitrogen-containing bisphosphonates. Prolonged use of bisphosphonates may lead to rare atypical femoral fractures, possibly due to rare mutations in the CYP1A1 gene.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Medicine, General & Internal
SeokJoon Hwang, Minsu Seo, Dongin Lim, Min Suk Choi, Jin-Woo Park, Kiyeun Nam
Summary: This literature review investigated the characteristics and management of bisphosphonate-associated bilateral atypical femoral fractures (AFFs). A comprehensive analysis of 43 patients with bilateral AFFs revealed that 67% had prodromal symptoms, 49% occurred simultaneously, and 51% occurred sequentially. X-ray was used for initial diagnosis, with 53% having complete fractures. Surgical treatment was performed for all patients, except for those with incomplete fractures who received either surgical or medical treatments. Teriparatide was the most commonly used medication after bisphosphonate discontinuation.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Endocrinology & Metabolism
Dennis M. Black, Katherine Condra, Annette L. Adams, Richard Eastell
Summary: Bisphosphonate use is associated with an increased risk of atypical femur fractures (AFFs), but it significantly reduces the risk of hip fractures and osteoporosis. The risk of AFFs varies between Asians and Caucasians, potentially due to differences in femoral geometry.
Article
Endocrinology & Metabolism
J. Everts-Graber, S. Reichenbach, B. Gahl, H. R. Ziswiler, U. Studer, T. Lehmann
Summary: Patients who received zoledronate after denosumab discontinuation had fewer vertebral fractures, while all subsequent therapies were able to maintain bone mineral density to some extent. Factors such as age, BMI, treatment duration, prior therapy, and BMD gains during denosumab treatment influenced bone mineral density loss, while bone turnover markers correlated with total hip bone loss and treatment duration.
Article
Endocrinology & Metabolism
Gareth Crouch, Nitesh D. Dhanekula, Karen Byth, Emma Burn, Sue Lynn Lau, Lillias Nairn, Liza Nery, Jean Doyle, Edward Graham, Andrew Ellis, Roderick J. Clifton-Bligh, Christian M. Girgis
Summary: The Sydney AFF score, based on demographic and femoral geometry variables, provides a quantitative means of identifying female patients with atypical femur fractures. In an independent validation set at a different center in Sydney, a score ≥ 2 demonstrated 73.3% sensitivity and 69.6% specificity for AFF.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Article
Endocrinology & Metabolism
Ian R. Reid, Anne M. Horne, Borislav Mihov, Sonja Bastin, Gregory D. Gamble
Summary: Bisphosphonates are commonly used for osteoporosis prevention and treatment, while NSAIDs are widely used by older adults at high fracture risk. A study reanalyzed data from a clinical trial of zoledronate and found that NSAID use did not affect the bone density or fracture risk reduction effects of zoledronate. The study concluded that NSAIDs do not interfere with the efficacy of potent bisphosphonates in terms of bone density or fracture.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Review
Medicine, General & Internal
YuLong Ouyang, ShuiLin Chen, Ting Wan, GuiHao Zheng, GuiCai Sun
Summary: The study found that teriparatide was more effective than bisphosphonates in preventing fractures in postmenopausal women with osteoporosis, including vertebral and non-vertebral fractures, with similar rates of adverse effects. More high-quality studies are needed to compare other factors such as costs and adverse reactions.
Review
Endocrinology & Metabolism
Wei Zhou, Jeroen G. J. van Rooij, Peter R. Ebeling, Annemieke J. M. H. Verkerk, M. Carola Zillikens
Summary: Recent studies suggest that atypical femur fractures (AFFs) may be associated with genetic components, with possible genetic variants identified in relation to AFF. Further research is needed to confirm these findings and explore additional gene variants involved in the pathogenesis of AFFs.
CURRENT OSTEOPOROSIS REPORTS
(2021)
Article
Environmental Sciences
Bastien Bourrion, Cecile Souty, Lucie Fournier, Ana-Maria Vilcu, Thierry Blanchon, Pierre-Yves Boelle, Thomas Hanslik, Mathilde Francois
Summary: The study found that in real life, the use of bisphosphonates does not appear to reduce hospitalization rates for hip fractures, possibly due to it being prescribed for primary prevention and for a duration too short to be effective.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Review
Medicine, General & Internal
Kaleen N. Hayes, Elizabeth M. Winter, Suzanne M. Cadarette, Andrea M. Burden
Summary: Bisphosphonates are the primary treatment for osteoporosis, and a drug holiday of two to three years is recommended for most patients after long-term use to reduce the risk of adverse events. Duration of bisphosphonate effects during the drug holiday and individual patient factors should be considered when determining the appropriate time to stop therapy.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Orthopedics
Jordan S. Cohen, Amil R. Agarwal, Matthew J. Kinnard, Savyasachi C. Thakkar, Gregory J. Golladay
Summary: The study aimed to evaluate the impact of antiosteoporotic medical therapy on the risk of periprosthetic fractures (PPFs) following hip arthroplasty for femoral neck fractures in older adults. Patients who initiated antiosteoporotic therapy within 1 year of surgery had a lower incidence of PPFs compared to those who did not receive treatment.
JOURNAL OF ARTHROPLASTY
(2023)
Article
Endocrinology & Metabolism
Jeremy Keng Meng Goh, Joyce Suang Bee Koh, Alvin Choong Meng Ng, Meng Ai Png, Tet Sen Howe
Summary: This case report presents a patient who developed bilateral atypical femur fractures after receiving denosumab treatment, despite having no prior history of bisphosphonate use. The patient's symptoms resolved with conservative management, but radiographic abnormalities persisted.
CALCIFIED TISSUE INTERNATIONAL
(2022)
Article
Endocrinology & Metabolism
Gregory A. Kline, Suzanne N. Morin, Lisa M. Lix, William D. Leslie
Summary: Bone mineral density (BMD) loss shows greater variability at shorter testing intervals, but this variability diminishes over longer intervals. Using reports of rapid BMD loss as an indication for antifracture medication initiation may not be accurate.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Gregory A. Kline, Suzanne N. Morin, Lisa M. Lix, William D. Leslie
Summary: This study examined medication adherence in women with osteoporosis before and after a fracture. The results show that many women experience a decline in medication adherence after a fracture, which is paradoxical to expectations. Fracture on therapy represents an important opportunity for clinicians to emphasize treatment adherence.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Medicine, Research & Experimental
Ahmad Oryan, Sonia Sahvieh
Summary: Osteoporosis mainly affects older individuals and postmenopausal women, with bisphosphonates (BPs) being the most effective medication for treatment. The use of zoledronate (Zol) within the BPs family shows promising results in improving bone density and preventing fractures, making it a potential treatment option for osteoporosis.